A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients.

摘要: Early imaging or blood biomarkers of tumor response are desperately needed to customize antiangiogenic therapy for cancer patients. Anti–vascular endothelial growth factor (VEGF) can “normalize” brain vasculature by decreasing vessel diameter and permeability, thinning the abnormally thick basement membrane. We hypothesized that extent vascular normalization will be predictive outcome anti-VEGF in glioblastoma. used advanced magnetic resonance methods monitor parameters treatment 31 recurrent glioblastoma patients enrolled a phase II trial cediranib, an oral pan-VEGF receptor tyrosine kinase inhibitor. evaluated correlation between clinical imaging–measured changes permeability/flow (i.e., K trans ) microvessel volume, change circulating collagen IV levels, all after single dose cediranib. Here, we show evaluation as early one day with cediranib is Changes , correlated duration overall survival and/or progression-free ( P = 0.004) (ρ 0.6; 0.001). The index described here should validated randomized trials. [Cancer Res 2009;69(13):5296–300]